Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). Specifically, it details the grant of conditional share awards on February 12, 2014, under the GlaxoSmithKline 2009 Performance Share Plan (PSP) and the 2009 Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not report operational financial results such as revenue, profit, cash flow, margins, debt, or liquidity for the period. Instead, it outlines performance targets used to determine executive compensation vesting:
- Adjusted Free Cash Flow Targets: Vesting thresholds range from a minimum of £13.68 billion (25% vesting) to a maximum of £16.22 billion (100% vesting).
- Share Pricing: Awards were calculated using an Ordinary Share price of £16.43 and an ADS price of US$54.17, based on closing prices from February 11, 2014.
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. The primary change reported is the execution of new equity incentive grants to Executive Directors and PDMRs effective February 12, 2014.
Guidance, Outlook, and Management Commentary
Performance Measures: The 2014 PSP awards are based on three equally weighted measures over a three-year period (January 1, 2014, to December 31, 2016):
- Total Shareholder Return (TSR): Relative performance against a comparator group of nine other global pharmaceutical companies. Vesting begins at 44% if ranked 5th (above median) and reaches maximum at ranks 1-3.
- Adjusted Free Cash Flow: Absolute targets ranging from £13.68bn to £16.22bn.
- R&D New Product Performance: Specific targets are withheld due to commercial sensitivity and will be disclosed at the end of the performance period. Vesting ranges from 25% at threshold to 100% at 122% of the threshold.
Deferred Bonus Plan: Executive Directors and Corporate Executive Team members deferred 25% of their 2013 bonus into shares, with the company providing matching awards subject to the same performance conditions as the PSP.
Risks and Contingencies: Awards are conditional and will lapse if performance targets are not met. Sir Andrew Witty's award includes a specific contingency where 25% of the award is subject to an additional two-year vesting period post-performance, forfeitable only if terminated for cause.
Important Facts for Investor Verification
- The filing contains no operational financial data (revenue, earnings, cash flow) for the period; it is strictly a disclosure of executive compensation grants.
- Executive compensation is heavily tied to Adjusted Free Cash Flow targets of £13.68bn to £16.22bn and relative TSR performance.
- R&D performance targets are not disclosed in this filing due to commercial sensitivity.
- Awards were granted on February 12, 2014, with a performance period ending December 31, 2016.
- Share prices used for calculation were £16.43 (Ordinary Shares) and US$54.17 (ADS).